[HTML][HTML] Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma
Oncotarget, 2015•ncbi.nlm.nih.gov
… We have developed a panel of molecularly targeted small-molecule inhibitors for direct
interrogation of primary leukemia patient samples that collectively informs pathway dependence,
and identifies candidate therapeutic options [3]. In our present study, we used a similarly
constructed panel of 116 targeted agents to screen MM cells, including BTZ and melphalan
resistant lines for the establishment of rationale drug combinations for resistant MM. The
compounds comprising this … The panel of small molecule inhibitors we used to screen …
interrogation of primary leukemia patient samples that collectively informs pathway dependence,
and identifies candidate therapeutic options [3]. In our present study, we used a similarly
constructed panel of 116 targeted agents to screen MM cells, including BTZ and melphalan
resistant lines for the establishment of rationale drug combinations for resistant MM. The
compounds comprising this … The panel of small molecule inhibitors we used to screen …
Abstract
Purpose
Despite significant therapeutic progress in multiple myeloma, drug resistance is uniformly inevitable and new treatments are needed. Our aim was to identify novel, efficacious small-molecule combinations for use in drug resistant multiple myeloma.
ncbi.nlm.nih.gov
以上显示的是最相近的搜索结果。 查看全部搜索结果